Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2026 16:25 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights

Announced partnership with Australian CRO to accelerate initiation of CLD-401 clinical trialThe Company has received feedback from the FDA through Type D interactions, and the Company believes its...
March 26, 2026 03:00 ET | Source: FoRx Therapeutics AG

FoRx Therapeutics Presents Preclinical Data at ACS Spring 2026, Confirming FORX-428's Potential for Best-in-Class PARG Inhibition

Presentation of the molecular structure, discovery, and preclinical data supporting the potential best-in-class profile of PARG inhibitor FORX-428.
March 25, 2026 12:15 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc. announces publication in Scientific Reports – Nature, of studies showing synergistic efficacy of its RXR agonist IRX4204 with the standard of care drug lenalidomide against multiple myeloma.

The Io Therapeutics, Inc. clinical stage anti-cancer RXR agonist compound demonstrated efficacy in models of human multiple myeloma.
March 25, 2026 07:30 ET | Source: EDAP TMS S.A.

EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue

EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue 39% Full-Year YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal One® System Sales and Growth in the Number of...
March 24, 2026 09:30 ET | Source: John Snow Labs

John Snow Labs Wins Real World Evidence Catalyst Challenge at PHUSE US Connect 2026

John Snow Labs recognized for its groundbreaking framework for automating oncology data abstraction at PHUSE US Connect 2026.
March 24, 2026 09:00 ET | Source: SurvivorRx

SurvivorRx Expands Personalized Supplement Routines as Oncologists Raise Concerns About Supplement Safety for Cancer Survivors

New oncologist formulated supplement systems aim to simplify wellness while addressing safety, dosing, and formulation challenges many survivors face.
March 24, 2026 08:45 ET | Source: Propanc Biopharma, Inc.

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

The goal is to strengthen our intellectual property and to better understand how PRP technology can overcome resistant tumors and age-related diseases.
March 24, 2026 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials

SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic...
March 23, 2026 11:15 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology Announces FDA Clearance of Investigator-Initiated IND to Advance Phase 1 Study in Recurrent High-Grade Glioma

Siren Biotechnology Announces FDA Clearance of Investigator-Initiated IND to Advance Phase 1 Study in Recurrent High-Grade Glioma
March 23, 2026 08:06 ET | Source: Inspire

Inspire and HPV Cancers Alliance Launch New Online Community for People Affected by HPV-Related Cancers

Arlington, VA, March 23, 2026 (GLOBE NEWSWIRE) -- Inspire, the world’s largest online community for patients and caregivers, today announced the launch of a new online community in partnership with...